New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies-Reference-Cited by-同舟云学术

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

Published:2016-06-27 Issue:1 Volume:13 Page:
ISSN:1742-2094
Container-title:Journal of Neuroinflammation
language:en
Short-container-title:J Neuroinflammation

Author:

Sehr T.,Proschmann U.,Thomas K.,Marggraf M.,Straube E.,Reichmann H.,Chan A.,Ziemssen T.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology,Immunology,General Neuroscience

Link

http://link.springer.com/content/pdf/10.1186/s12974-016-0635-2

Reference40 articles.

1. Hutchinson M. Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007;3:259–68.

2. Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis. 2008;5:16–22.

3. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–46.

4. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.

5. Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72:396–401.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review;Clinical Pharmacokinetics;2024-04-07

2. Serum Evaluation of Helicobacter pylori in Patients with Multiple Sclerosis;Archives of Neuroscience;2023-08-06

3. Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges;International Journal of Molecular Sciences;2023-07-22

4. Influence of exercise on quantity and deformability of immune cells in multiple sclerosis;Frontiers in Neurology;2023-05-18

5. Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis;Therapeutic Advances in Neurological Disorders;2023-01